Image
Practice Point
Adjuvant chemotherapy for residual disease – Triple negative breast cancer
For patients with triple negative breast cancer with residual disease after neoadjuvant chemotherapy, consider the addition of capecitabine to a post-neoadjuvant anthracycline-taxane regimen.
In high-risk, triple-negative patients not achieving pCR after standard neoadjuvant ChT, the addition of 6–8 cycles of capecitabine postoperatively may be considered (Level of evidence – I)
Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, etc.), optional
How this guidance was developed
No evidence-based source recommendation was identified for this topic, which was considered an important aspect of care. This practice point was developed using an expert consensus process. A source recommendation (date of evidence review not reported) in the recent ESMO 2019 clinical practice guidelines (Europe) which was graded ‘C’ (using ESMO methods adapted from the Infectious Diseases Society of America-United States Public Health Service Grading System), supports this practice point.
Adjuvant chemotherapy for residual disease – Triple negative breast cancer
Practice Point
For patients with triple negative breast cancer with residual disease after neoadjuvant chemotherapy, consider the addition of capecitabine to a post-neoadjuvant anthracycline-taxane regimen.
Principles in action
Safe and quality care
Image
Communication
No evidence-based source recommendation was identified for this topic, which was considered an important aspect of care. This practice point was developed using an expert consensus process. A source recommendation (date of evidence review not reported) in the recent ESMO 2019 clinical practice guidelines (Europe) which was graded ‘C’ (using ESMO methods adapted from the Infectious Diseases Society of America-United States Public Health Service Grading System), supports this practice point.